[{"id":10,"name":"KIT Exon 17","description":null,"variants":[{"id":64,"gene_id":29,"name":"D816V","description":"KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.","created_at":"2015-04-02T15:01:35.121Z","updated_at":"2015-04-02T15:01:35.121Z"},{"id":69,"gene_id":29,"name":"EXON 17 MUTATIONS","description":"c-KIT exon 17 mutations lie within the TK2 domain, containing the activation loop of the protein. In cell lines, mutations within this domain have been shown to be sensitive to imatinib. However, in double KIT mutants in which the exon 17 mutation is a secondary mutation, cell lines have shown resistance to both imatinib and sunitinib.","created_at":"2015-04-02T15:01:35.211Z","updated_at":"2015-04-02T15:01:35.211Z"},{"id":69,"gene_id":29,"name":"EXON 17 MUTATIONS","description":"c-KIT exon 17 mutations lie within the TK2 domain, containing the activation loop of the protein. In cell lines, mutations within this domain have been shown to be sensitive to imatinib. However, in double KIT mutants in which the exon 17 mutation is a secondary mutation, cell lines have shown resistance to both imatinib and sunitinib.","created_at":"2015-04-02T15:01:35.211Z","updated_at":"2015-04-02T15:01:35.211Z"}]},{"id":11,"name":"KIT Exon 11","description":null,"variants":[{"id":65,"gene_id":29,"name":"EXON 11 MUTATIONS","description":"c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.","created_at":"2015-04-02T15:01:35.138Z","updated_at":"2015-04-02T15:01:35.138Z"},{"id":65,"gene_id":29,"name":"EXON 11 MUTATIONS","description":"c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.","created_at":"2015-04-02T15:01:35.138Z","updated_at":"2015-04-02T15:01:35.138Z"},{"id":65,"gene_id":29,"name":"EXON 11 MUTATIONS","description":"c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.","created_at":"2015-04-02T15:01:35.138Z","updated_at":"2015-04-02T15:01:35.138Z"},{"id":65,"gene_id":29,"name":"EXON 11 MUTATIONS","description":"c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.","created_at":"2015-04-02T15:01:35.138Z","updated_at":"2015-04-02T15:01:35.138Z"},{"id":65,"gene_id":29,"name":"EXON 11 MUTATIONS","description":"c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.","created_at":"2015-04-02T15:01:35.138Z","updated_at":"2015-04-02T15:01:35.138Z"},{"id":65,"gene_id":29,"name":"EXON 11 MUTATIONS","description":"c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.","created_at":"2015-04-02T15:01:35.138Z","updated_at":"2015-04-02T15:01:35.138Z"},{"id":66,"gene_id":29,"name":"INTERNAL DUPLICATION","description":"c-KIT internal duplications have been observed in exon 11, within the juxtamembrane domain. In a case study of an anal melanoma patient harboring this event, imatinib confered marked response. Also, cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.","created_at":"2015-04-02T15:01:35.155Z","updated_at":"2015-04-02T15:01:35.155Z"},{"id":71,"gene_id":29,"name":"L576P","description":"KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.","created_at":"2015-04-02T15:01:35.247Z","updated_at":"2015-04-02T15:01:35.247Z"},{"id":71,"gene_id":29,"name":"L576P","description":"KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.","created_at":"2015-04-02T15:01:35.247Z","updated_at":"2015-04-02T15:01:35.247Z"},{"id":71,"gene_id":29,"name":"L576P","description":"KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.","created_at":"2015-04-02T15:01:35.247Z","updated_at":"2015-04-02T15:01:35.247Z"},{"id":72,"gene_id":29,"name":"V654A","description":"KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.","created_at":"2015-04-02T15:01:35.266Z","updated_at":"2015-04-02T15:01:35.266Z"},{"id":72,"gene_id":29,"name":"V654A","description":"KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.","created_at":"2015-04-02T15:01:35.266Z","updated_at":"2015-04-02T15:01:35.266Z"}]},{"id":1,"name":"Imatinib Resistance","description":"While imatinib has shown to be incredibly successful in treating philadelphia chromosome positive CML, patients that have shown primary or secondary resistance to the drug have been observed to harbor T315I and E255K ABL kinase domain mutations. These mutations, among others, have been observed both in primary refractory disease and acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations have also been shown to confer resistance to imatinib. ","variants":[{"id":2,"gene_id":4,"name":"BCR-ABL T315I","description":"While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of seleciton have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.","created_at":"2015-04-02T15:01:33.917Z","updated_at":"2015-04-02T15:01:33.917Z"},{"id":2,"gene_id":4,"name":"BCR-ABL T315I","description":"While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of seleciton have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.","created_at":"2015-04-02T15:01:33.917Z","updated_at":"2015-04-02T15:01:33.917Z"},{"id":3,"gene_id":4,"name":"BCR-ABL E255K","description":"While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of seleciton have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.","created_at":"2015-04-02T15:01:33.938Z","updated_at":"2015-04-02T15:01:33.938Z"},{"id":96,"gene_id":38,"name":"D842I","description":"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","created_at":"2015-04-02T15:01:35.747Z","updated_at":"2015-04-02T15:01:35.747Z"},{"id":97,"gene_id":38,"name":"D842V","description":"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","created_at":"2015-04-02T15:01:35.765Z","updated_at":"2015-04-02T15:01:35.765Z"},{"id":97,"gene_id":38,"name":"D842V","description":"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","created_at":"2015-04-02T15:01:35.765Z","updated_at":"2015-04-02T15:01:35.765Z"},{"id":97,"gene_id":38,"name":"D842V","description":"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","created_at":"2015-04-02T15:01:35.765Z","updated_at":"2015-04-02T15:01:35.765Z"},{"id":97,"gene_id":38,"name":"D842V","description":"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","created_at":"2015-04-02T15:01:35.765Z","updated_at":"2015-04-02T15:01:35.765Z"},{"id":98,"gene_id":38,"name":"D842Y","description":"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","created_at":"2015-04-02T15:01:35.783Z","updated_at":"2015-04-02T15:01:35.783Z"},{"id":99,"gene_id":38,"name":"DEL I843","description":"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","created_at":"2015-04-02T15:01:35.801Z","updated_at":"2015-04-02T15:01:35.801Z"},{"id":100,"gene_id":38,"name":"DI842-843IM","description":"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).","created_at":"2015-04-02T15:01:35.818Z","updated_at":"2015-04-02T15:01:35.818Z"}]},{"id":2,"name":"ALK Fusions","description":"ALK fusion positive non-small cell lung cancer (NSCLC) is treated as its own subset of NSCLC. Many ALK fusions that have been seen as recurrent in cancer serve to increase the activity of the ALK oncogene relative to normal cells. While EML4 is the most common fusion partner, other 5' partners have been observed. The EML4-ALK fusion has shown sensitivity to targeted tyrosine kinase inhibitors such as crizotinib. ","variants":[{"id":5,"gene_id":1,"name":"EML4-ALK","description":"The EML4-ALK fusion has been seen in non-small cell lung cancer, and appears to be an alternative mechanism for ALK activation. Cells with this fusion have been shown to be sensitive to the ALK inhibitor crizotinib.","created_at":"2015-04-02T15:01:33.976Z","updated_at":"2015-04-02T15:01:33.976Z"},{"id":6,"gene_id":1,"name":"EML4-ALK C1156Y","description":"In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib.","created_at":"2015-04-02T15:01:33.992Z","updated_at":"2015-04-02T15:01:33.992Z"},{"id":7,"gene_id":1,"name":"EML4-ALK L1196M","description":"In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib.","created_at":"2015-04-02T15:01:34.009Z","updated_at":"2015-04-02T15:01:34.009Z"}]},{"id":6,"name":"TKI Resistance","description":"EGFR pathway activation is a nearly ubiquitous hallmark of cancer. Many tyrosine kinase inhibitors have been developed to target EGFR pathway activity. One such inhibitor, erlotinib, has demonstrated efficacy in an EGFR over-active setting. However, the T790M missense mutation has shown to confer resistance to this inhibitor in cell lines and case studies.  ","variants":[{"id":34,"gene_id":19,"name":"T790M","description":"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. The third generation TKI's are being developed with this resistance problem in mind, and early stage experiments have shown some efficacy of these drugs in previously resistant tumors with mutant EGFR.","created_at":"2015-04-02T15:01:34.524Z","updated_at":"2015-04-02T15:01:34.524Z"},{"id":34,"gene_id":19,"name":"T790M","description":"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. The third generation TKI's are being developed with this resistance problem in mind, and early stage experiments have shown some efficacy of these drugs in previously resistant tumors with mutant EGFR.","created_at":"2015-04-02T15:01:34.524Z","updated_at":"2015-04-02T15:01:34.524Z"},{"id":77,"gene_id":30,"name":"G12C","description":"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.","created_at":"2015-04-02T15:01:35.373Z","updated_at":"2015-04-02T15:01:35.373Z"},{"id":78,"gene_id":30,"name":"G12D","description":"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib.","created_at":"2015-04-02T15:01:35.395Z","updated_at":"2015-04-02T15:01:35.395Z"},{"id":144,"gene_id":53,"name":"AMPLIFICATION","description":"MET amplification, like EGFR T790M, has been shown to be capable of driving acquired resistance to dacomitinib in patients with lung adenocarcinoma.","created_at":"2015-04-02T15:01:36.640Z","updated_at":"2015-04-02T15:01:36.640Z"},{"id":145,"gene_id":30,"name":"G12V","description":"KRAS G12V, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.","created_at":"2015-04-02T15:01:36.656Z","updated_at":"2015-04-02T15:01:36.656Z"},{"id":146,"gene_id":30,"name":"G12A","description":"KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.","created_at":"2015-04-02T15:01:36.673Z","updated_at":"2015-04-02T15:01:36.673Z"}]},{"id":3,"name":"Crizotinib Resistance","description":"The ALK oncogene has long been considered a driving factor in non-small cell lung cancer (NSCLC). The targeted tyrosine kinase inhibitor criztonib has shown to be effective in ALK-mutant NSCLC. However, in patients that have shown acquired resistance to crizotinib, missense mutations in the tyrosine kinase domain have shown to drive this resistance. ","variants":[{"id":6,"gene_id":1,"name":"EML4-ALK C1156Y","description":"In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib.","created_at":"2015-04-02T15:01:33.992Z","updated_at":"2015-04-02T15:01:33.992Z"},{"id":7,"gene_id":1,"name":"EML4-ALK L1196M","description":"In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, this variant has been shown to confer resistance to crizotinib.","created_at":"2015-04-02T15:01:34.009Z","updated_at":"2015-04-02T15:01:34.009Z"},{"id":8,"gene_id":1,"name":"F1174L","description":"ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.","created_at":"2015-04-02T15:01:34.026Z","updated_at":"2015-04-02T15:01:34.026Z"}]},{"id":4,"name":"Other V600's","description":"While BRAF V600E is nearly ubiquitous in many cancer types, other V600 variants have also been observed and studied to a lesser degree. At first approximation, many of these variants seem to behave similarly to V600E, and treatment with dabrafenib has been shown to be effective. ","variants":[{"id":11,"gene_id":5,"name":"V600D","description":"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.","created_at":"2015-04-02T15:01:34.086Z","updated_at":"2015-04-02T15:01:34.086Z"},{"id":13,"gene_id":5,"name":"V600E/V600M","description":"A case study of a single patient harboring both a V600E and a V600M mutation, dabrafenib was shown to acheive clinical response.","created_at":"2015-04-02T15:01:34.126Z","updated_at":"2015-04-02T15:01:34.126Z"},{"id":15,"gene_id":5,"name":"V600M","description":"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.","created_at":"2015-04-02T15:01:34.162Z","updated_at":"2015-04-02T15:01:34.162Z"},{"id":16,"gene_id":5,"name":"V600R","description":"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.","created_at":"2015-04-02T15:01:34.179Z","updated_at":"2015-04-02T15:01:34.179Z"}]},{"id":7,"name":"HER2 Activating","description":"HER2-positive breast cancer is widely recognized as a molecular subtype of breast cancer. While amplification of ERBB2 is a common mechanism for activation of the pathway, missense mutations have also demonstrated activation potential. These activating missense mutations also confer senstivity to the targeted therapeutic neratinib. ","variants":[{"id":35,"gene_id":20,"name":"D769H","description":"ERBB2 D769H was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","created_at":"2015-04-02T15:01:34.546Z","updated_at":"2015-04-02T15:01:34.546Z"},{"id":36,"gene_id":20,"name":"D769Y","description":"ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","created_at":"2015-04-02T15:01:34.565Z","updated_at":"2015-04-02T15:01:34.565Z"},{"id":38,"gene_id":20,"name":"G309A","description":"ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","created_at":"2015-04-02T15:01:34.604Z","updated_at":"2015-04-02T15:01:34.604Z"},{"id":41,"gene_id":20,"name":"P780INS","description":"ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","created_at":"2015-04-02T15:01:34.661Z","updated_at":"2015-04-02T15:01:34.661Z"},{"id":43,"gene_id":20,"name":"R896C","description":"ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","created_at":"2015-04-02T15:01:34.696Z","updated_at":"2015-04-02T15:01:34.696Z"},{"id":44,"gene_id":20,"name":"V777L","description":"ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","created_at":"2015-04-02T15:01:34.725Z","updated_at":"2015-04-02T15:01:34.725Z"},{"id":45,"gene_id":20,"name":"V842I","description":"ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2012). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.","created_at":"2015-04-02T15:01:34.742Z","updated_at":"2015-04-02T15:01:34.742Z"}]},{"id":8,"name":"ESR1 Ligand-Binding Domain","description":"ER-positive breast cancer is the most common of the breast cancer subtypes. Hormone therapy has been widely effective in treating the disease, however sequencing of resistant patients has uncovered a number of missense mutations in mediating this resistance. Many of these mutations lie within the ligand-binding domain, and contribute to constitutive activity of the receptor. This has lead to the development of estrogen receptor degrading agents such as fulvestrant, which have shown early efficacy in clinical trials.  ","variants":[{"id":46,"gene_id":21,"name":"L536Q","description":"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","created_at":"2015-04-02T15:01:34.761Z","updated_at":"2015-04-02T15:01:34.761Z"},{"id":46,"gene_id":21,"name":"L536Q","description":"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","created_at":"2015-04-02T15:01:34.761Z","updated_at":"2015-04-02T15:01:34.761Z"},{"id":47,"gene_id":21,"name":"N538G","description":"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. N538G is one of these ligand binding domain  , and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","created_at":"2015-04-02T15:01:34.780Z","updated_at":"2015-04-02T15:01:34.780Z"},{"id":47,"gene_id":21,"name":"N538G","description":"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. N538G is one of these ligand binding domain  , and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","created_at":"2015-04-02T15:01:34.780Z","updated_at":"2015-04-02T15:01:34.780Z"},{"id":48,"gene_id":21,"name":"Y537C","description":"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain  , and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","created_at":"2015-04-02T15:01:34.799Z","updated_at":"2015-04-02T15:01:34.799Z"},{"id":48,"gene_id":21,"name":"Y537C","description":"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain  , and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","created_at":"2015-04-02T15:01:34.799Z","updated_at":"2015-04-02T15:01:34.799Z"},{"id":49,"gene_id":21,"name":"Y537N","description":"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain  , and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","created_at":"2015-04-02T15:01:34.820Z","updated_at":"2015-04-02T15:01:34.820Z"},{"id":49,"gene_id":21,"name":"Y537N","description":"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain  , and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","created_at":"2015-04-02T15:01:34.820Z","updated_at":"2015-04-02T15:01:34.820Z"},{"id":50,"gene_id":21,"name":"Y537S","description":"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain  , and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","created_at":"2015-04-02T15:01:34.838Z","updated_at":"2015-04-02T15:01:34.838Z"},{"id":50,"gene_id":21,"name":"Y537S","description":"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain  , and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.","created_at":"2015-04-02T15:01:34.838Z","updated_at":"2015-04-02T15:01:34.838Z"}]},{"id":9,"name":"FGFR fusions","description":"FGFR fusions have been demonstrated across many cancer types to have oncogenic potential. FGFR2 and FGFR3 have been shown to be fused to many 3' partners, which may act as a vehicle for pathway activation. Treatment of cell lines harboring FGFR2 fusions with pazopanib has shown mild \"anti-tumor\" activities, and both ponatinib and pazopanib have shown efficacy in case studies.  ","variants":[{"id":51,"gene_id":22,"name":"FGFR2-MGEA5","description":"In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.","created_at":"2015-04-02T15:01:34.858Z","updated_at":"2015-04-02T15:01:34.858Z"},{"id":52,"gene_id":23,"name":"FGFR3-BAIAP2L1","description":"In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.","created_at":"2015-04-02T15:01:34.876Z","updated_at":"2015-04-02T15:01:34.876Z"},{"id":53,"gene_id":23,"name":"FGFR3-TACC3","description":"In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.","created_at":"2015-04-02T15:01:34.898Z","updated_at":"2015-04-02T15:01:34.898Z"}]},{"id":12,"name":"NPM1 Exon 12","description":"NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.","variants":[{"id":86,"gene_id":35,"name":"W288FS","description":"NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).","created_at":"2015-04-02T15:01:35.555Z","updated_at":"2015-04-02T15:01:35.555Z"},{"id":86,"gene_id":35,"name":"W288FS","description":"NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).","created_at":"2015-04-02T15:01:35.555Z","updated_at":"2015-04-02T15:01:35.555Z"},{"id":86,"gene_id":35,"name":"W288FS","description":"NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).","created_at":"2015-04-02T15:01:35.555Z","updated_at":"2015-04-02T15:01:35.555Z"},{"id":86,"gene_id":35,"name":"W288FS","description":"NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).","created_at":"2015-04-02T15:01:35.555Z","updated_at":"2015-04-02T15:01:35.555Z"}]},{"id":13,"name":"PTEN Loss-of-Function","description":"PTEN loss is a common event in breast cancer, as well as others. The most common single nucleotide variant resulting in PTEN loss is a R233 nonsense mutation. Cell lines harboring this mutation behave similarly to cell lines harboring larger insertion or deletion events, in that they both respond to PI3K-mTOR inhibitors with impeded growth. ","variants":[{"id":108,"gene_id":41,"name":"R233*","description":"PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.","created_at":"2015-04-02T15:01:35.966Z","updated_at":"2015-04-02T15:01:35.966Z"},{"id":108,"gene_id":41,"name":"R233*","description":"PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.","created_at":"2015-04-02T15:01:35.966Z","updated_at":"2015-04-02T15:01:35.966Z"}]},{"id":14,"name":"Motesanib Resistance","description":"RET activation is a common oncogenic marker of medullary thyroid carcinoma. Treatment of these patients with the targeted therapeutic motesanib has shown to be effective. However, the missense mutations C634W and M918T have shown to confer motesanib resistance in cell lines. ","variants":[{"id":110,"gene_id":42,"name":"C634W","description":"RET C639W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C639W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.","created_at":"2015-04-02T15:01:36.001Z","updated_at":"2015-04-02T15:01:36.001Z"},{"id":111,"gene_id":42,"name":"M918T","description":"RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.","created_at":"2015-04-02T15:01:36.019Z","updated_at":"2015-04-02T15:01:36.019Z"}]},{"id":15,"name":"TSC Loss","description":"Inactivating events in TSC1 and TSC2 have been observed in a number of cancer types. Cell lines and case studies have shown that in the loss of TSC, the mTOR inhibitor everolimus has seen significant anti-tumorigenic activity. ","variants":[{"id":122,"gene_id":46,"name":"FRAMESHIFT TRUNCATION","description":"In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.","created_at":"2015-04-02T15:01:36.229Z","updated_at":"2015-04-02T15:01:36.229Z"},{"id":122,"gene_id":46,"name":"FRAMESHIFT TRUNCATION","description":"In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.","created_at":"2015-04-02T15:01:36.229Z","updated_at":"2015-04-02T15:01:36.229Z"},{"id":123,"gene_id":46,"name":"LOSS-OF-FUNCTION","description":"In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.","created_at":"2015-04-02T15:01:36.246Z","updated_at":"2015-04-02T15:01:36.246Z"},{"id":124,"gene_id":47,"name":"LOSS-OF-FUNCTION","description":"In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.","created_at":"2015-04-02T15:01:36.265Z","updated_at":"2015-04-02T15:01:36.265Z"}]},{"id":5,"name":"BRCA Germline Variants","description":"BRCA germline variants have long been recognized as important potential predictors of breast and ovarian cancer risk. ","variants":[{"id":129,"gene_id":6,"name":"LOSS-OF-FUNCTION","description":"BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.","created_at":"2015-04-02T15:01:36.367Z","updated_at":"2015-04-02T15:01:36.367Z"},{"id":130,"gene_id":7,"name":"LOSS-OF-FUNCTION","description":"BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.","created_at":"2015-04-02T15:01:36.384Z","updated_at":"2015-04-02T15:01:36.384Z"}]}]